The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
Intel Corp. and General Electric Co. are about to jump into the healthcare pool together, the Wall Street Journal reported.
A press conference is slated for April 2 in New York, hosted by Intel CEO Paul Otellini and GE CEO Jeffrey Immelt, where the two are expected to announce their collaboration.
Intel, the microprocessing giant, isn’t involved in healthcare but has been working for years to build a business in the sector.
Insulet Corp. took home the Best New Product award in the medical and science category at the 2009 Edison Awards for its OmniPod insulin pump.
The Google-sponsored awards are given to products that “excel in marketplace, innovation, marketplace success, technological innovation, market structure, innovation, and societal impact.” Past winners include Apple Computer, Johnson & Johnson and Chrysler.
Clinical Data Inc. agreed to sell its Cogenics division to Beckman Coulter Inc. for about $17 million.
The Newton-based genomics firm said the deal is part of its strategy to divest non-core businesses and focus on targeted therapeutics and biomarker development.
The Cogenics business provides outsourced genomics services. It will be integrated into Orange County, Calif.-based Beckman Coulter’s Agencourt Biosciences genomics services business.
Clinical Data will get about $15.4 million when the deal closes and get to keep roughly $2 million in cash from Cogenics just before the sale.
Inverness Medical Innovations Inc. added an ovarian cancer expert to its board of directors.
The Waltham-based diagnostics maker said it named Dr. Eli Adashi to its board and compensation committee.
People suffering from toenail fungus might be one step closer to a cure, thanks to Nomir Medical Technologies‘ new direct optical energy device.
The company’s Noveon system, which uses infrared technology to wipe out bacteria and fungal infections, showed in recent trials that 74 percent of the 32 subjects with onychomycosis, or toenails infected by fungus, had significantly less fungus after two treatments.
Older heart disease patients with drug-eluting stents fare better when it comes to heart attacks and mortality rates than patients with bare metal stents, according to a study funded by the federal Health & Human Services dept.’s Agency for Healthcare Research and Quality.
A study by Interleukin Genetics Inc. shows that women are more likely to suffer vertebral fractures and osteoporosis if they carry a specific gene variation.
The Waltham-based biomarker maker, which is flirting with a de-listing by the New York Stock Exchange, said its clinical study of 1,200 Asian women that Korean women are 70 percent more disposed to vertebral fracture if they carry a genetic variation in the IL-10 gene.
An online publishing company out of Providence created a searchable version of the monolithic American Recovery and Reinvestment Act of 2009, commonly known as the “stimulus bill.”
The ARRA, which included billions of dollars in government funds for life science research, comes in at more than 400 pages.
Tizra is a start-up that helps publishers distribute e-books, according to the Xconomy website.
Terason Corp. will continue to distribute its handheld ultrasound equipment to a network of over 2,000 hospitals for at least another three years.
The deal is with Premier healthcare alliance, a Charlotte, N.C.-based network of 2,100 U.S. hospitals and more than 54,000 other healthcare sites. No specific dollar amounts were given by either company.
Terason, a Burlington company that makes diagnostic ultrasound equipment, inked the original deal April 1, 2006.
The former president of Boston Scientific Corp.‘s peripheral interventions division joined the board of directors at Avantis Medical Systems Inc.
The Sunnyvale, Calif., company manufactures a catheter-based colonoscope called the Third Eye Retroscope, a miniature video endoscope that can see behind the folds of the human colon.
Jenusaitis worked for the Natick-based medical devices giant for 15 years before leaving the company in 2005.
Already facing a possible delisting from NASDAQ, Exact Sciences Corp. reported more bad news.
Sales for the genomics firm slipped dramatically in 2008, pushing the company into the red for the year and offsetting cost-cutting moves made in July when it shed its R&D staff. Exact Sciences laid off eight employees, leaving a skeleton crew of four staff members at its Marlborough headquarters.
